

Investors Newsletter

Number 4

November 1, 2014



We are pleased to inform you that we have received our new trading symbol. We are now trading on the OTCQB market under the symbol – EQUR. Please look us up. We continue to be a fully-reporting company with the United States Securities and Exchange Commission using our new name, E-QURE Corp., a company incorporated in the State of Delaware, USA.

We have established a wholly-owned subsidiary, domiciled in Israel, ESQURE Ltd, to manage all production activity, and manage, in a later stage of development, the second generation of our DST device.

We have completed the acquisition of the all the sample prototype devices and all proprietary intellectual property including the product manufacturing documents from third parties through ESQURE.

We have also several of our devices to be used in our FDA clinical trial. These were converted to 110V, tested, re-packaged and are ready to ship to the USA where our FDA trials will take place.



E-QURE Corp. 20 w 64 St. New York, NY 10023, USA.
www.e-quire.com
info@e-quire.com

The Company has established a Scientific Advisory Board and proudly announced the nomination of two prominent members, Prof. Avi Ohri and Dr. Benzi Wiener. We are in the process of adding one or two additional members from the US wound care medical community.

As we have previously reported, the company filed an S1 (Registration Statement) with the SEC to allow share trading to our investors. We will publicly announce when we anticipate that our registration will be effective so investors can deposit their shares certificate in their accounts and be ready to trade their E-QURE shares on the OTCQB market.

The company is pleased to announce that has also added a new Board Member, Dr. Michael Sessler, a prominent businessman with medical education. We intend to add additional members, including highly qualified persons from the US business community, to our Board of Directors.

The company is participating in the upcoming Medica Convention in mid-Nov., to be held in Dusseldorf, Germany, at which we will present our E-QURE BST Device to the medical device community, and re-establish business connections for Europe.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. We are using forward-looking statements, when we discuss items in this document. These forward-looking statements and their implications are based on the current expectations of the management of E-QURE only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of E-QURE to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, E-QURE undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting E-QURE, reference is made to E-QURE's reports filed from time to time with the Securities and Exchange Commission.